Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: IL-37 protects against airway remodeling by reversing bronchial epithelial–mesenchymal transition via IL-24 signaling pathway in chronic asthma

Fig. 2

IL-24 induced EMT in BEAS-2B cells via the ERK1/2 and STAT3 pathways. a BEAS-2B cells were treated with 100 ng/ml IL-24 at different time points, and the activation of STAT3, ERK1/2, p38MAPK, NF-κb p65 and JNK signaling pathways was analyzed by western blot. b The activation of the p-STAT3/STAT3 pathway was analyzed by western blot. BEAS-2B cells were treated with 100 ng/ml IL-24 for 48 h with or without tofacitinib, PD98059 or DMSO pretreatment for 1 h. c The activation of the p-ERK1/2/ERK1/2 pathway was analyzed by western blot. BEAS-2B cells were treated with 100 ng/ml IL-24 for 48 h with or without tofacitinib, PD98059 or DMSO pretreatment for 1 h. d Quantification of E-cadherin, vimentin and α-SMA mRNA expression in BEAS-2B cells treated with 100 ng/ml IL-24 for 24 h with or without tofacitinib, PD98059 or DMSO pretreatment for 1 h by RT–qPCR. Representative immunoblot analysis (e) and quantification (f) of E-cadherin, vimentin and α-SMA protein expression in BEAS-2B cells exposed to 100 ng/ml IL-24 for 48 h with or without tofacitinib, PD98059 or DMSO pretreatment for 1 h. Bar diagrams and data are presented as the mean ± standard deviation (SD) from three replicate experiments. Beas-2B cells were treated with completed 1640 culture medium alone as a control group. *vs. control group; # vs. IL-24 group. *,#P < 0.05; **,##P < 0.01; ***,###P < 0.001; ****,####P < 0.0001

Back to article page